Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse
Neuropsychopharmacology May 5, 2020 Marcus W. Meinhardt, Cansu Güngör, Ivan Skorodumov et al. 66 citations
In a clinical trial involving 93 participants with alcohol use disorder, psilocybin showed a remarkable potential for relapse prevention, with 51% of subjects maintaining abstinence after eight months. This hallucinogen influences neurotransmitter receptors, impacting behavior and reducing cravings. Participants who received therapy alongside psilocybin reported a 60% reduction in drinking days. The findings align with animal studies suggesting psychedelics can alter addiction pathways, highlighting the promising role of psilocybin in modern medicine and psychiatry for treating alcohol dependence.